离心式左心室辅助装置桥接后心脏移植的性别结局
该研究基于UNOS数据库分析2010-2018年间3010例经新型耐久LVAD(HeartMate III或HeartWare)桥接后接受原位心脏移植的患者,其中76.7%为男性。经倾向评分匹配和多因素Cox分析,调整相关协变量后,年龄和心衰病因而非性别是死亡的独立预测因素;结论认为现代新型LVAD桥接后男女移植结局相当。
要点
- 新型LVAD桥接后心脏移植,匹配队列中性别不影响移植后并发症和死亡。
- 年龄和心衰病因是死亡的独立预测因素,而非性别。
核心结论
- 匹配女性经新型HeartWare或HeartMate III LVAD桥接后接受OHT,移植后结局与男性相当。
- 1年随访生存不受性别影响,而由年龄增加、术前肾功能较差和心衰病因等既定危险因素驱动。
研究设计与样本
- 查询UNOS数据库,研究2010-2018年间经新型耐久LVAD(HeartMate III或HeartWare)桥接后接受OHT的受者。
- 共纳入3010例患者,76.7%为男性;采用倾向评分匹配和Cox多因素分析评估调整合并症后的性别差异。
主要发现
- 调整相关协变量后,年龄和心衰病因而非性别是死亡的独立预测因素。
- 匹配队列中性别不影响移植后结局,包括肾衰竭、脑血管事件、移植物排斥、功能状态或死亡(所有P > .05)。
- OHT后1年生存率男性为90.5%,女性为92.8%(P = .058)。
临床怎么用
- 经新型LVAD桥接的心脏移植候选者,性别不应作为移植后结局风险的独立分层依据。
- 应重点关注年龄、术前肾功能和心衰病因等既定危险因素以优化移植后管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior studies demonstrated that female sex is associated with an increased mortality after orthotopic heart transplantation (OHT). The impact of sex on OHT outcomes after bridging with newer-generation durable left ventricular assist devices (LVADs) remains unclear. METHODS: The United Network for Organ Sharing database was queried to study OHT recipients bridged with a newer-generation LVAD (ie, HeartMate III or HeartWare) between 2010 and 2018. The primary outcome was mortality at 30 and 90-days and 1-year. Secondary outcomes included rates of posttransplant complications. Propensity score matching and Cox multivariable analysis were used to assess comorbidity-adjusted sex differences in outcomes. RESULTS: A total of 3010 patients (76.7% male) bridged with newer-generation LVADs underwent OHT. After adjusting for relevant covariates, both age and heart failure etiology, but not sex, were independent predictors of mortality. In the matched cohorts, sex did not affect posttransplant outcomes, including renal failure, cerebrovascular events, allograft rejection, functional status, or mortality (all P > .05). Survival at 1-year after OHT was 90.5% in males and 92.8% in females (P = .058). CONCLUSIONS: Among 3010 OHT recipients, matched females bridged with newer-generation HeartWare or HeartMate III LVADs have comparable posttransplant outcomes compared with males. Furthermore, survival at 1-year follow-up was not affected by sex; instead, it was driven by well-established risk factors including increased age, worse preoperative renal function, and heart failure etiology. These data suggest that considerable progress has been made in mitigating sex differences in heart failure outcomes in the modern era.
引用
- Huckaby LV, Seese LM, Aranda-Michel E, et al. Sex-Based Heart Transplant Outcomes After Bridging With Centrifugal Left Ventricular Assist Devices. Ann Thorac Surg. 2020. PMID: 32376349. doi:10.1016/j.athoracsur.2020.03.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。